Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma

Seminars in Oncology

Volumn 43, Issue 1, 2016, Pages 86-96

  Neto, Antonio Galvao ^a   Whitaker, April ^a   Pei, Zhiheng ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemoprevention; Esophageal adenocarcinoma; Innate immunity; Microbiome

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE;

BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CHRONIC INFLAMMATION; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS DYSPLASIA; FRUIT; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM EXPOSURE; MICROBIOME; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; SMOKING; STOMACH ACID SECRETION; STOMACH EMPTYING; VEGETABLE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CHEMOPROPHYLAXIS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL TRACT; INTESTINE FLORA; MICROBIOLOGY; MICROFLORA;

ADENOCARCINOMA; ANIMALS; ANTI-BACTERIAL AGENTS; CARCINOGENESIS; CHEMOPREVENTION; CYCLOOXYGENASE 2 INHIBITORS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; RISK FACTORS;

EID: 84960359863     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.005     Document Type: Review

References (133)

1. L. Yang, X. Lu, C.W. Nossa, F. Francois, R.M. Peek, and Z. Pei Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome Gastroenterology 137 2 2009 588 597
2. J. Lederberg Infectious history Science 288 2000 287 293
3. R.E. Ley, D.A. Peterson, and J.I. Gordon Ecological and evolutionary forces shaping microbial diversity in the human intestine Cell 124 2006 837 848
4. J. Peterson, S. Garges, M. Giovanni, and et al. The NIH Human Microbiome Project Genome Res 19 12 2009 2317 2323
5. L.M. Proctor The Human Microbiome Project in 2011 and beyond Cell Host Microbe 10 4 2011 287 291
6. R.E. Ley, P.J. Turnbaugh, S. Klein, and J.I. Gordon Microbial ecology: human gut microbes associated with obesity Nature 444 2006 1022 1023
7. A.K. Greiner, R.V. Papineni, and S. Umar Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome Am J Physiol Gastrointest Liver Physiol 307 1 2014 G1 15
8. C.J. Rogers, K.S. Prabhu, and M. Vijay-Kumar The microbiome and obesity-an established risk for certain types of cancer Cancer J 20 3 2014 176 180
9. A.S. Neish Microbes in gastrointestinal health and disease Gastroenterology 136 2009 65 80
10. M. Arumugam, J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D.R. Mende, and et al. Enterotypes of the human gut microbiome Nature 473 7346 2011 174 180
11. K.Y. Wolin, and G.A. Colditz Cancer and beyond: healthy lifestyle choices for cancer survivors J Natl Cancer Inst 105 2013 593 594
12. A.M. O'Hara, and F. Shanahan Gut microbiome: mining for therapeutic potential Clin Gastroenterol Hepatol 5 2007 274 284
13. B.S. Ramakrishna Role of the gut microbiome in human nutrition and metabolism J Gastroenterol Hepatol 28 S4 2013 9 17
14. J.H. Ooi, Y. Li, C.J. Rogers, and et al. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis J Nutr 143 2013 1679 1686
15. A. Dzutsev, R.S. Goldszmid, S. Viaud, L. Zitvogel, and G. Trinchieri The role of the microbiota in inflammation, carcinogenesis, and cancer therapy Eur J Immunol 45 2015 17 31
16. H. Chu, and S.K. Mazmanian Innate immune recognition of the microbiome promotes host-microbial symbiosis Nat. Immunol 14 2013 668 675
17. N. Kamada, G.Y. Chen, N. Inohara, and G. Nunez Control of pathogens and pathobionts by the gut microbiome Nat. Immunol 14 2013 685 690
18. C.A. Lozupone, J.I. Stombaugh, J.I. Gordon, J.K. Jansson, and R. Knight Diversity, stability and resilience of the human gut microbiome Nature 489 2012 220 230
19. M.A. Underwood Intestinal dysbiosis: novel mechanisms by which gut microbes trigger and prevent disease Prev. Med 65 2014 133 137
20. J. Henao-Mejia, E. Elinav, C. Jin, and et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity Nature 482 2012 179 181
21. M. Vijay-Kumar, J.D. Aitken, F.A. Carvalho, T.C. Cullender, S. Mwangi, S. Srinivasan, and et al. Metabolic syndrome and altered gut microbiome in mice lacking Toll-like receptor 5 Science 328 2010 228 231
22. M. Wang, C. Karlsson, C. Olsson, I. Adlerberth, A.E. Wold, D.P. Strachan, and et al. Reduced diversity in the early fecal microbiome of infants with atopic eczema J Allergy Clin Immunol 121 2008 129 134
23. Z. Wang, E. Klipfell, B.J. Bennett, and et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 472 2011 57 63
24. L. Wen, R.E. Ley, P.Y. Volchkov, and et al. Innate immunity and intestinal microbiome in the development of Type 1 diabetes Nature 455 2008 1109 1113
25. C. de Martel, J. Ferlay, S. Franceschi, and et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis Lancet Oncol 13 2012 607 615
26. X. Zhang, Z. Zhang, B. Zheng, Z. He, G. Winberg, and I. Ernberg An update on viral association of human cancers Arch Virol 158 2013 1433 1443
27. J. Ng, and J. Wu Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences Hepat Mon 12 2012 e7635
28. M. Tommasino The human papillomavirus family and its role in carcinogenesis Semin Cancer Biol 26 2014 13 21
29. P.E. Castle, S.L. Hillier, L.K. Rabe, and et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV) Cancer Epidemiol Biomarkers Prev 10 2001 1021 1027
30. J. Koshiol, M. Sklavos, N. Wentzensen, and et al. Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study Int J Cancer 134 2014 411 425
31. V. Ciminale, F. Rende, U. Bertazzoni, and M.G. Romanelli HTLV-1 and HTLV-2: highly similar viruses with distinct oncogenic properties Front Microbiol 5 2014 398
32. J. Henao-Mejia, E. Elinav, C.A. Thaiss, P. Licona-Limon, and R.A. Flavell Role of the intestinal microbiome in liver disease J Autoimmun 46 2013 66 73
33. P.S. Moore, and Y. Chang Why do viruses cause cancer? Highlights of the first century of human tumour virology Nat Rev Cancer 10 2010 878 889
34. Schistosomes, liver flukes and Helicobacter pylori IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994 IARC Monogr Eval Carcinog Risks Hum 61 1994 1 241
35. D.J. Kim, J.H. Park, L. Franchi, S. Backert, and G. Nunez The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1beta production in Helicobacter pylori infected dendritic cells Eur J Immunol 43 2013 2650 2658
36. C.S. Plottel, and M.J. Blaser Microbiome and malignancy Cell Host Microbe 10 2011 324 335
37. M.L. Yamamoto, and R.H. Schiestl Intestinal microbiome and lymphoma development Cancer J 20 3 2014 190 194
38. R.F. Schwabe, and C. Jobin The microbiome and cancer Nat Rev Cancer 13 2013 800 812
39. L. Yang, and Z. Pei Bacteria, inflammation, and colon cancer World J Gastroenterol 12 42 2006 6741 6746
40. C. de Martel, A.E. Llosa, G.D. Friedman, and et al. Helicobacter pylori infection and development of pancreatic cancer Cancer Epidemiol Biomarkers Prev 17 5 2008 1188 1194
41. B. Lindkvist, D. Johansen, A. Borgström, and J. Manjer A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer BMC Cancer 8 2008 321
42. D.S. Michaud, and J. Izard Microbiota, oral microbiome, and pancreatic cancer Cancer J 20 3 2014 203 206
43. D.S. Michaud, K. Joshipura, E. Giovannucci, and C.S. Fuchs A prospective study of periodontal disease and pancreatic cancer in US male health professionals J Natl Cancer Inst 99 2 2007 171 175
44. M. Cho, J. Carter, S. Harari, and Z. Pei the interrelationships of the gut microbiome and inflammation in colorectal carcinogenesis Clin Lab Med 34 4 2014 699 710
45. B. Signat, C. Roques, P. Poulet, and et al. Fusobacterium nucleatum in periodontal health and disease Curr Issues Mol Biol 13 2 2011 25 36
46. S. Dulal, and T.O. Keku Gut microbiome and colorectal adenomas Cancer J 20 3 2014 225 231
47. R. Francescone, V. Hou, and S.I. Grivennikov Microbiome, inflammation, and cancer Cancer J 20 3 2014 181 189
48. S. Krishnan, and G.D. Eslick Streptococcus bovis infection and colorectal neoplasia: a meta-analysis Colorectal Dis 16 9 2014 672 680
49. D. Collins, A.M. Hogan, and D.C. Winter Microbial and viral pathogens in colorectal cancer Lancet Oncol 12 5 2011 504 512
50. S. Rakoff-Nahoum, and R. Medzhitov Toll-like receptors and cancer Nat Rev Cancer 9 2009 57 63
51. S. Pushalkar, X. Ji, Y. Li, C. Estilo, R. Yegnanarayana, B. Singh, X. Li, and D. Saxena Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma BMC Microbiol 12 2012 144
52. B.L. Schmidt, J. Kuczynski, A. Bhattacharya, and et al. Changes in abundance of oral microbiota associated with oral cancer PLoS One 9 6 2014 e98741
53. W. Xu, L. Yang, P. Lee, and et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma Am J Clin Exp Urol 2 1 2014 57 61
54. C. Werts, S. Rubino, A. Ling, S.E. Girardin, and D.J. Philpott Nod-like receptors in intestinal homeostasis, inflammation, and cancer J Leukoc Biol 90 2011 471 482
55. D. Nesic, Y. Hsu, and C.E. Stebbins Assembly and function of a bacterial genotoxin Nature 429 2004 429 433
56. G. Cuevas-Ramos, C.R. Petit, I. Marcq, M. Boury, E. Oswald, and J.P. Nougayrede Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells Proc Natl Acad Sci USA 107 2010 11537 11542
57. J.C. Arthur, E. Perez-Chanona, M. Muhlbauer, and et al. Intestinal inflammation targets cancer-inducing activity of the microbiome Science 338 2012 120 123
58. F. Carbonero, A.C. Benefiel, A.H. Alizadeh-Ghamsari, and H.R. Gaskins Microbial pathways in colonic sulfur metabolism and links with health and disease Front Physiol 3 2012 448
59. J.G. Fox, and T.C. Wang Inflammation, atrophy, and gastric cancer J Clin Invest 117 2007 60 69
60. M.R. Rubinstein, X. Wang, W. Liu, Y. Hao, G. Cai, and Y.W. Han Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin Cell Host Microbe 14 2013 195 206
61. S.R. Gill, M. Pop, R.T. Deboy, and et al. Metagenomic analysis of the human distal gut microbiome Science 312 2006 1355 1359
62. C. Hur, M. Miller, C.Y. Kong, and et al. Trends in esophageal adenocarcinoma incidence and mortality Cancer 119 6 2013 1149 1158
63. G. Edgren, H.O. Adami, E. Weiderpass, and O. Nyrén A global assessment of the oesophageal adenocarcinoma epidemic Gut 62 10 2013 1406 1414
64. J. Lagergren, and P. Lagergren Recent developments in esophageal adenocarcinoma CA Cancer J Clin 63 4 2013 232 248
65. L. Alexandre, E. Long, and I.L. Beales Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma World J Gastrointest Pathophysiol 5 4 2014 534 549
66. S. Hardikar, L. Onstad, P.L. Blount, R.D. Odze, B.J. Reid, and T.L. Vaughan The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus PLoS One 8 1 2013 e52192
67. E. Long, and I.L. Beales The role of obesity in oesophageal cancer development Therap Adv Gastroenterol 7 6 2014 247 268
68. M.B. Cook, F. Kamangar, D.C. Whiteman, and et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: A pooled analysis from the international BEACON consortium J Natl Cancer Inst 102 2010 1344 1353
69. American Lung Association Research and Program Services Epidemiology and Statistics Unit. Trends in Tobacco Use July 2011 American Lung Association
70. S. Nie, T. Chen, X. Yang, P. Huai, and M. Lu Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis Dis Esophagus 27 7 2014 645 653
71. K.M. Brawner, C.D. Morrow, and P.D. Smith Gastric microbiome and gastric cancer Cancer J 20 3 2014 211 216
72. I. Cho, S. Yamanishi, L. Cox, and et al. Antibiotics in early life alter the murine colonic microbiome and adiposity Nature 488 7413 2012 621 626
73. T.A. Suzuki, and M. Worobey Geographical variation of human gut microbial composition Biol Lett 10 2 2014 20131037
74. K.M. Keeney, S. Yurist-Doutsch, M.C. Arrieta, and B.B. Finlay Effects of antibiotics on human microbiome and subsequent disease Annu Rev Microbiol 68 2014 217 235
75. O.M. Pirzada, J. McGaw, C.J. Taylor, and M.L. Everard Improved lung function and body mass index associated with long-term use of Macrolide antibiotics J Cyst Fibros 2 2 2003 69 71
76. L. Yang, N. Chaudhary, J. Baghdadi, and Z. Pei Microbiome in reflux disorders and esophageal adenocarcinoma Cancer J 20 3 2014 207 210
77. Z. Pei, E.J. Bini, L. Yang, M. Zhou, F. Francois, and M.J. Blaser Bacterial biota in the human distal esophagus Proc Natl Acad Sci U S A 101 12 2004 4250 4255
78. Z. Pei, L. Yang, R.M. Peek Jr, S.M. Levine, D.T. Pride, and M.J. Blaser Bacterial biota in reflux esophagitis and Barrett's esophagus World J Gastroenterol 11 46 2005 7277 7283
79. S. Macfarlane, E. Furrie, G.T. Macfarlane, and J.F. Dillon Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus Clin Infect Dis 45 1 2007 29 38
80. G.L. Osias, M.Q. Bromer, R.M. Thomas, and et al. Esophageal bacteria and Barrett's esophagus: a preliminary report Dig Dis Sci 49 2 2004 228 236
81. L. Yang, F. Francois, and Z. Pei Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus Clin Cancer Res 18 8 2012 2138 2144
82. S. Calatayud, E. García-Zaragozá, C. Hernández, and et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying Am J Physiol Gastrointest Liver Physiol 283 6 2002 G1360 G1367
83. Y.P. Fan, S. Chakder, F. Gao, and S. Rattan Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction Am J Physiol Gastrointest Liver Physiol 280 1 2001 G32 G42
84. R.E. Verbeek, P.D. Siersema, F.J. Ten Kate, and et al. Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression J Gastroenterol 49 7 2014 1121 1134
85. K.T. Wilson, S. Fu, K.S. Ramanujam, and S.J. Meltzer Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res 58 14 1998 2929 2934
86. B.J. Colleypriest, S.G. Ward, and D. Tosh How does inflammation cause Barrett's metaplasia? Curr Opin Pharmacol 9 6 2009 721 726
87. J.S. Lee, T.Y. Oh, B.O. Ahn, H. Cho, W.B. Kim, Y.B. Kim, Y.J. Surh, H.J. Kim, and K.B. Hahm Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: clue for the chemoprevention of esophageal carcinoma by antioxidants Mutat Res 480-481 2001 189 200
88. P.C. Konturek, A. Nikiforuk, J. Kania, M. Raithel, E.G. Hahn, and S. Mühldorfer Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors Dig Dis Sci 49 7-8 2004 1075 1083
89. J.M. O'Riordan, M.M. Abdel-latif, N. Ravi, and et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus Am J Gastroenterol 100 6 2005 1257 1264
90. C.J. Buskens, B.P. Van Rees, A. Sivula, and et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus Gastroenterology 122 7 2002 1800 1807
91. J. Hu, R. Jacinto, C. McCall, and L. Li Regulation of IL-1 receptor-associated kinases by lipopolysaccharide J Immunol 168 8 2002 3910 3914
92. C. de Martel, A.E. Llosa, S.M. Farr, and et al. Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma J Infect Dis 191 5 2005 761 767
93. W. Ye, M. Held, J. Lagergren, and et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia J Natl Cancer Inst 96 5 2004 388 396
94. T. Rokkas, D. Pistiolas, P. Sechopoulos, I. Robotis, and G. Margantinis Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis Clin Gastroenterol Hepatol 5 12 2007 1413 1417
95. F.J. Xie, Y.P. Zhang, Q.Q. Zheng, and et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis World J Gastroenterol 19 36 2013 6098 6107
96. L.A. Fischbach, H. Nordenstedt, J.R. Kramer, and et al. The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis Helicobacter 17 3 2012 163 175
97. A. Raghunath, A.P. Hungin, D. Wooff, and S. Childs Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review BMJ 326 7392 2003 737
98. T. Koike, S. Ohara, H. Sekine, and et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis Aliment Pharmacol Ther 15 6 2001 813 820
99. K. Tsukada, T. Miyazaki, H. Katoh, and et al. The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori Eur J Gastroenterol Hepatol 17 10 2005 1025 1028
100. T. Koike, S. Ohara, Y. Inomata, Y. Abe, K. Iijima, and T. Shimosegawa The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan Inflammopharmacology 15 2 2007 61 64
101. J.C. Wu, F.K. Chan, S.K. Wong, Y.T. Lee, W.K. Leung, and J.J. Sung Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis Aliment Pharmacol Ther 16 3 2002 545 552
102. F. Francois, J. Roper, N. Joseph, and et al. The effect of Helicobacter pylori eradication on meal-associated changes in plasma ghrelin and leptin BMC Gastroenterol 11 2011 37
103. J.A. Lane, L.J. Murray, I.M. Harvey, J.L. Donovan, P. Nair, and R.F. Harvey Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study Aliment Pharmacol Ther 33 8 2011 922 929
104. S.J. Spechler, P. Sharma, R.F. Souza, J.M. Inadomi, and N.J. Shaheen American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus Gastroenterology 140 3 2011 e18 e52
105. S.J. Spechler, and R.F. Souza Barrett's esophagus N Engl J Med 371 9 2014 836 845
106. A.C. Strauss, A.T. Agoston, P.S. Dulai, A. Srivastava, and R.I. Rothstein Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study Surg Endosc 28 12 2014 3366 3372
107. C.R. Subramanian, and G. Triadafilopoulos Endoscopic treatments for dysplastic Barrett's esophagus: resection, ablation, what else? World J Surg 39 2015 597 605
108. L.C. Hillman, L. Chiragakis, B. Shadbolt, G.L. Kaye, and A.C. Clarke Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus Aliment Pharmacol Ther 27 4 2008 321 326
109. B.T. Cooper, W. Chapman, C.S. Neumann, and J.C. Gearty Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence Aliment Pharmacol Ther 23 6 2006 727 733
110. S. Singh, S.K. Garg, P.P. Singh, P.G. Iyer, and H.B. El-Serag Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis Gut 63 8 2014 1229 1237
111. T. Miyashita, F.A. Shah, J.W. Harmon, and et al. Do proton pump inhibitors protect against cancer progression in GERD? Surgery today 43 8 2013 831 837
112. T. Ohta, H. Tajima, A. Yachie, and et al. Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components Int J Oncol 15 1999 33 39
113. A. De Milito, M.L. Marino, and S. Fais A rationale for the use of proton pump inhibitors as antineoplastic agents Curr Pharm Des 18 10 2012 1395 1406
114. M.M. Abdel-Latif, J. O'Riordan, H.J. Windle, and et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy Ann Surg 239 4 2004 491 500
115. T.D. Gilmore, and M. Herscovitch Inhibitors of NF-kappaB signaling: 785 and counting Oncogene 25 51 2006 6887 6899
116. C.E. Woodall, Y. Li, Q.H. Liu, J. Wo, and R.C. Martin Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation Anticancer Drugs 20 6 2009 437 443
117. H. Neumann, K. Mönkemüller, M. Vieth, and P. Malfertheiner Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options Dig Dis 27 1 2009 18 23
118. N.S. Buttar, K.K. Wang, O. Leontovich, and et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus Gastroenterology 122 4 2002 1101 1112
119. D.M. Nguyen, P. Richardson, and H.B. El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus Gastroenterology 138 7 2010 2260 2266
120. E.I. Heath, M.I. Canto, S. Piantadosi, and et al. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial J Natl Cancer Inst 99 7 2007 545 557
121. D. Das, A.P. Chilton, and J.A. Jankowski Chemoprevention of oesophageal cancer and the AspECT trial Recent Results Cancer Res 181 2009 161 169
122. D. Das, S. Ishaq, R. Harrison, and et al. Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introducion of a national randomized trial Am J Gastroenterol 103 5 2008 1079 1089
123. J. Jankowski, and H. Barr Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base BMJ 332 2006 1512
124. J. Cuzick, M.A. Thorat, C. Bosetti, and et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population Ann Oncol 2014 pii:mdu225
125. M.F. Buas, and T.L. Vaughan Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease Semin Radiat Oncol 23 1 2013 3 9
126. S. Sadeghi, C.J. Bain, N. Pandeya, P.M. Webb, A.C. Green, and D.C. Whiteman Australian Cancer Study. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus Cancer Epidemiol Biomarkers Prev 17 5 2008 1169 1178
127. P.A. Gatenby, J.R. Ramus, C.P. Caygill, M.C. Winslet, and A. Watson Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort Eur J Cancer Prev 18 5 2009 381 384
128. B.J. Whittle Nitric oxide-modulating agents for gastrointestinal disorders Expert Opin Investig Drugs 14 11 2005 1347 1358
129. P. Kubes, and J.L. Wallace Nitric oxide as a mediator of gastrointestinal mucosal injury? - Say it ain't so Mediators Inflamm 4 6 1995 397 405
130. M.N. Muscará, and J.L. Wallace Nitric oxide. V. therapeutic potential of nitric oxide donors and inhibitors Am J Physiol 276 6 Pt 1 1999 G1313 G1316
131. Y.P. Fan, S. Chakder, F. Gao, and S. Rattan Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction Am J Physiol Gastrointest Liver Physiol 280 1 2001 G32 G42
132. E. Chrysos, G. Tzovaras, E. Epanomeritakis, and et al. Erythromycin enhances oesophageal motility in patients with gastro-oesophageal reflux Aust NZ J Surg 71 2 2001 98 102
133. S. Shirazi, K. Schulze-Delrieu, T. Custer-Hagen, C.K. Brown, and J. Ren Motility changes in opossum esophagus from experimental esophagitis Dig Dis Sci 34 11 1989 1668 1676